Leitlinie „Behandlung der Akne“ - AWMF
Leitlinie „Behandlung der Akne“ - AWMF
Leitlinie „Behandlung der Akne“ - AWMF
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
013/017 - Behandlung <strong>der</strong> Akne aktueller Stand: 02/2010<br />
korrigierte Fassung: 10/2011<br />
274. Larsen TH, Jemec GB. Acne: comparing hormonal approaches to antibiotics and<br />
isotretinoin. Expert Opin Pharmacother. 2003; 4: 1097-103.<br />
275. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated<br />
with isotretinoin: a systematic review. Semin Cutan Med Surg. 2007; 26: 210-20.<br />
276. European Medicines Agency. Annex III; Amended summary of product<br />
characteristics of the reference member state. 2003. URL:<br />
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Isotret<br />
inoin_29/WC500010881.pdf [2011-09-30]<br />
277. Arowojolu AO, Gallo MF, Lopez LM, Grims DA, Garner SE. Combined oral<br />
contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2009.<br />
278. van Vloten WA, Sigurdsson V. Selecting an oral contraceptive agent for the treatment<br />
of acne in women. Am J Clin Dermatol. 2004; 5: 435-41.<br />
279. Fotherby K, Caldwell AD. New progestogens in oral contraception. Contraception.<br />
1994; 49: 1-32.<br />
280. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive<br />
containing drospirenone to a triphasic preparation containing norgestimate in acne<br />
treatment. Cutis. 2004; 74: 123-30.<br />
281. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research<br />
and clinical perspectives. J Invest Dermatol. 2002; 119: 992-1007.<br />
282. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003; 63:<br />
463-92.<br />
283. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen<br />
homeostasis in human skin. J Invest Dermatol. 2001; 116: 793-800.<br />
284. Gollnick H, Albring M, Brill K. [The effectiveness of oral cyproterone acetate in<br />
combination with ethinylestradiol in acne tarda of the facial type]. Ann Endocrinol<br />
(Paris). 1999; 60: 157-66.<br />
285. Audebert A, Emperaire JC, Gauthier A, Hallonet P, Hedon B, Lopes P, Quereux C,<br />
Roulier R. [Multicentric clinical trial of a combination of 35 micrograms of<br />
ethinylestradiol and 2 mg of cyproterone acetate]. Rev Fr Gynecol Obstet. 1991; 86:<br />
697-9.<br />
286. Kaiser E. [Clinical experience with Diane-35, currently the lowest dose<br />
antiandrogenic hormonal ovulation inhibitor, in mild to mo<strong>der</strong>ative androgenization in<br />
the female]. Geburtshilfe Frauenheilkd. 1986; 46: 738-42.<br />
287. Vartiainen M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with<br />
a combiphasic desogestrel-containing oral contraceptive and a preparation containing<br />
cyproterone acetate. Eur J Contracept Reprod Health Care. 2001; 6: 46-53.<br />
288. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and<br />
cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic<br />
ovarian syndrome. Hum Reprod. 2001; 16: 36-42.<br />
289. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol<br />
in the treatment of acne. Results of a multicenter study. Acta Obstet Gynecol Scand<br />
Suppl. 1986; 134: 29-32.<br />
Seite 123 von 136
Change language